Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 1997

View Archived Issues

UCSF receives NIH funding for research into anticancer protease inhibitors

Genentech granted U.S. patents for factor VIII

Selective 5-HT1Dalpha receptor agonists from MS&D

Astra prepares NOS inhibitors

Antiviral dihydropyrans from Biota

Synthelabo prepares serotonergic agents

Arzneimittelwerk describes novel antiepileptic agents

Synthelabo reports agents for urinary incontinence

First launch for new indication of cabergoline

Aldara approved in U.S.

MDR-reversing agents described by Nikken Chemicals

Fujsawa selects adenosine A1 receptor antagonist for development

Fujisawa describes new oral cephem antibiotic

Eisai prepares potent antitumor agents

TX-1877: new hypoxic cell radiation enhancer

Lilly granted rights to gene/protein involved in islet neogenesis

RPR cleared to market Taxotere in Malaysia and Hungary

Encouraging phase III results reported for lamivudine as hepatitis B treatment

Wyeth-Ayerst and Elan develop new formulation of Lodine

Milestone reached in Genome Therapeutics/Astra H. pylori collaboration

Progress in Cubist/Bristol-Myers Squibb antiinfective collaboration

Treatment for rhinitis undergoes further development in Australia

Hybridon selects HPV drug candidate

Encouraging results from preclinical trial of Atlantic's RSV therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...